Alvotech Completes $100m Private Placement
Second Round Adds $35m After $65m First Round In October
Alvotech has completed a $100m private placement after concluding a second found of funding worth $35m. The move comes as the company prepares to commercialize its portfolio of biosimilars through a series of partnerships.
You may also be interested in...
Icelandic biosimilars specialist Alvotech has eased some of its liability to bondholders following a debt-to-equity conversion, at the same time as it improved terms and extended its maturity.
Cipla has expanded its partnership with Alvotech to cover the commercialization of four biosimilars in Australia and New Zealand, building on an existing alliance covering South Africa and emerging markets.
A network of marketing deals with key players across the globe has laid the foundations for Alvotech’s biosimilars to be marketed worldwide, the company’s founder and chairman tells Generics Bulletin in an exclusive interview.